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Ser/Thr protein phosphatase 5 (PP5) regulates several signaling-cascades that suppress growth and/or facilitate apoptosis in response to genomic
stress. The expression of PP5 is responsive to hypoxia inducible factor-1 (HIF-1) and estrogen, which have both been linked to the progression of
human breast cancer. Still, it is not clear if PP5 plays a role in the development of human cancer. Here, immunostaining of breast cancer tissue-
microarrays (TMAs) revealed a positive correlation between PP5 over-expression and ductal carcinoma in situ (DCIS; P value 0.0028), invasive
ductal carcinoma (IDC; P value 0.012) and IDC with metastases at the time of diagnosis (P value 0.0001). In a mouse xenograft model, the
constitutive over-expression of PP5 was associated with an increase in the rate of tumor growth. In a MCF-7 cell culture model over-expression
correlated with both an increase in the rate of proliferation and protection from cell death induced by oxidative stress, UVC-irradiation, adriamycin,
and vinblastine. PP5 over-expression had no apparent effect on the sensitivity ofMCF-7 cells to taxol or rapamycin.Western analysis of extracts from
cells over-expressing PP5 revealed a decrease in the phosphorylation of known substrates for PP5. Together, these studies indicate that elevated levels
of PP5 protein occur in human breast cancer and suggest that PP5 over-expression may aid tumor progression.
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The reversible phosphorylation of proteins plays a key role
in the regulation of many signaling networks that control cell
growth, differentiation, senescence and programmed cell death
(apoptosis) [1]. Protein phosphorylation occurs principally onAbbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal
carcinoma; FACS, fluorescence activated cell sorting; ASK1, apoptosis signal
regulating kinase 1; HIF-1, hypoxia inducible factor 1; MKK4, Map-kinase
kinase-4; DNA-PKcs, DNA-dependent ser/thr protein kinase; ATM, ataxia-
telangiectasia mutated-kinase; ATR, ATM/rad 3 related kinase; GR, glucocorti-
coid receptor; ER, estrogen receptor; PR, progesterone receptor; JNK, c-Jun N-
terminal kinase
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doi:10.1016/j.bbadis.2008.01.004serine, threonine and tyrosine residues, and N500 kinases that
catalyze the phosphorylation of proteins have been identified in
the human genome [2]. Protein dephosphorylation is catalyzed
by protein phosphatases, and in humans there are three major
types of protein phosphatases: tyrosine phosphatases (PTPases),
serine/threonine phosphatases (PPases) and “dual specificity”
phosphatases (DSPases). To date, the aberrant actions of several
“key” protein kinases have been shown to promote or facilitate
the development of human cancers, and in the last decade drugs
to alter the actions of these kinases (i.e. trastuzumab, imatinib,
bevacizumab, gefitinib and cetuximab) have been developed into
new treatment options for the medical management of human
cancers. In contrast, although ser/thr protein phosphatases have
also been implicated in the regulation of many signal transduc-
tion cascades that control growth [3–6], relatively little is known
about the roles played by individual phosphatases in the devel-
opment or progression of human cancer.
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has emerged as a potentially key regulator of cell growth. PP5 is
found in association with several proteins that influence intra-
cellular signaling-cascades initiated by hormones (i.e. gluco-
corticoids) or cellular stress (i.e. hypoxia, oxidative stress and
DNA-damage). In glucocorticoid signaling, the association of
PP5 with the glucocorticoid receptor (GR)-heat shock protein-
90 (Hsp-90) complex occurs in cells that have not encountered
stress [7–9], and PP5 suppresses a GR-dependent signaling
cascade leading to the phosphorylation of the p53 tumor sup-
pressor protein [10–12]. Thus, PP5 appears to prevent the aber-
rant activation of basal p53 in cells that have not encountered
genomic stress. In response to genomic stress, PP5 associates
with several stress-induced protein complexes. The molecular
events controlling the intracellular translocation of PP5 are
not yet clear. Still, in response to either prolonged hypoxia or
acute oxidative stress, PP5 binds to ASK1 (apoptosis signal-
regulating kinase 1) [13,14]. This interaction prevents the sus-
tained activation of JNK (c-Jun-N-terminal kinase) and apo-
ptosis by suppressing ASK1 dependent activation of MKK4
(Map-Kinase-Kinase-4) [13–15]. In response to DNA damage,
PP5 binds to DNA-PKcs (DNA-dependent ser/thr protein ki-
nase) [16], ATM (ataxia–telangiectasia mutated-kinase) [17],
and ATR (ATM/rad 3 related kinase) [18]. The interaction of
PP5 with DNA-PKcs results in the dephosphorylation of a
functional site on DNA-PKcs (thr2609), suggesting PP5 acts as a
negative regulator of DNA-PKcs [16]. In contrast, in ATM-and
ATR-signaling PP5 appears to function as a positive regulator,
for the suppression of PP5 expression prevents ATM/ATR-
mediated G-1 growth arrest [17]. PP5 has also been reported to
negatively regulate Raf-1, with PP5 mediated dephosphoryla-
tion of Ser338 inhibiting Raf-1 activity and down stream signal-
ing toMEK [19,20]. Together, these studies suggest that PP5 is a
potentially important regulator of signaling networks that allow
a cell to respond appropriately to growth factors and stress.
In humans PP5 is expressed in most, if not all, tissues.
Studies into the mechanisms controlling the expression of PP5
indicate that it is transcriptionally responsive to 17 β-estradiol
(E2) [21,22] and the activation of hypoxia inducible factor-1
(HIF-1), which have both been associated with the aggressive
development of human breast cancer [23,24]. In culture, the
constitutive over expression of PP5 allows estrogen-dependent
MCF-7 cells to grow in estrogen depleted media [21]. Here, PP5
protein levels are compared in samples of human tumor tissue and
breast epithelium from non-malignant tissue, revealing a positive
correlation between PP5 expression and human breast cancer.
The consequences of sustained PP5 over-expression in a normal
estrogen environment were also assessed using a xenograft
mouse model, and the effects of PP5 over-expression on cellular
responses to stress are studied in human breast adenocarcinoma
(MCF-7) cell lines that constitutively express high levels of PP5.
2. Materials and methods
2.1. Materials
Tissue culture medium was purchased from Gibco™ (Invitrogen Corpora-
tion). t-butyl-hydroperoxide, and monoclonal anti-actin antibodies (AC-40)were purchased from Sigma. Adriamycin (doxorubicin) was purchased from
Calbiochem. Antibodies recognizing p38, c-Jun and proteins phosphorylated at
specific sites [c-Jun at Ser63; SEK1/MKK4 at Thr261; p38 MAPK (Thr180/
Tyr182), p44/p42-MAPK/ERK1/2 (Thr202/Tyr204), JNK (Thr183/Tyr185)] and anti
Poly (ADP-ribose) polymerase (PARP) antibody were purchased from Cell
Signaling (Beverly, MA). Rabbit polyclonal antibodies recognizing PP5 were
generated against a synthetic 15-amino acid peptide identical to a C-terminal
region of PP5 [10,11]. Rabbit polyclonal antibodies recognizing GFP and PP5
monoclonal antibodies were purchased from BD-Biosciences-Clontech.
2.2. Cell culture
Human MCF-7 breast carcinoma cell lines were obtained from the American
Type TissueCollection.MCF-7 cells were cultured inDulbecco'smodified Eagle's
medium containing L-Glutamine (DMEM) supplemented with 10% bovine-serum,
streptomycin (0.1 μg/ml) and penicillin (100U/ml). All cell cultures were routinely
passed when 85–90% confluent unless indicated otherwise.
2.3. Transient transfections
Cell transfection assays were conducted as described previously [10,11].
Briefly, cells were plated at a density of 5×105 cells/ 60-mm tissue culture dish
and incubated overnight in DMEM supplemented with 10% FCS. After ∼24 h
the cells were transfected with 2.0 μg of plasmid DNA using Lipofectamine
(Invitrogen).
2.4. Construction of stable cell lines over-expressing PP5
MCF-7-PP5h1 cells in which the expression of human PP5 is regulated
by tetracycline-responsive promoter and operator system were developed by
stable transfection of MCF-7 tet-off cells (Clontech, Palo Alto, CA) with a pBI-
derived plasmid encoding full length human PP5. Tetracycline-inducible PP5
expression in MCF-7-PP5h1 cells has been characterized previously [21].
MCF-7 cell lines that constitutively express a PP5 c-terminal EGFP fusion-
protein (i.e. MCF-7-PP5s and MCF-7-PP5j) were generated by subcloning
human PP5 into the pEGFP-N1 expression vector (Clontech) and transfecting
into MCF-7 cells. EGFP-control cell lines were produced by transfecting
MCF-7 cells with the pEGFP-N1 plasmid. Plasmid uptake was facilitated by
electroporation (Gene Pulser II, Bio-Rad Labs) as follows: 1×106 cells were
suspended in 160 μl of DMEM medium with 10 μg of plasmid in 4 mm gap
cuvettes and subjected to a modified long-duration procedure (max μF cap,
500 V, repeated pulses for a total time of 10 ms). Transfected cells were
incubated for 48 h in 100 mm plates until they were 80–90% confluent. Stably
transfected cells were generated by selection with 0.6 mg/mL of Geneticin™.
Several clones expressing PP5-EGFP or EGFP produced via separate trans-
fections were isolated and then propagated. PP5 levels in the cell lines were
characterized by western and FACS-analysis.
2.5. Western blotting
Cells grown in 60 mm plates were washed twice with ice-cold phosphate-
buffered saline (PBS) and then lysed by scraping in 250 μl of lysis buffer
[0.25 M Tris–HCl/0.2% SDS, pH 6.8, 20% glycerol, 4% SDS, 1 mM NaF,
10 mM β-glycerol phosphate, and 1 μl/ml protease inhibitor cocktail (Sigma)].
Lysates were clarified by centrifugation at 13,000 ×g for 5 min, and an aliquot of
the supernatant was removed for protein determination. Protein concentrations
were determined using a Bio-Rad Dc protein assay, using bovine-serum albumin
(BSA) for standards. The remaining supernatant was added to an equal volume
of 2× sample buffer (120 mM Tris–HCl, pH 7.4, 200 mM dithiothreitol, 20%
glycerol, 4% SDS, and 0.02% bromphenol blue). Typically, 25–30 μg of protein
was then separated by electrophoresis on 10% SDS-polyacrylamide gels. Pro-
teins were then electrophoretically transferred to Immobilon-P (Millipore
Corporation) and placed in blocking buffer [Tris–HCl, pH 7.4,150 mM NaCl
and 5% nonfat milk or 5% BSA with Tween-20 (TBS-T)] for 1 h Immuno-
blotting was performed with the indicated primary antibody using either goat
anti-mouse (Pharmingen, San Diego, CA) or goat anti-rabbit secondary (Pro-
mega, Madison, WI) antibodies. Antibody association was detected employing
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the protocols of the manufacturer. Quantification of the signal was achieved
using a Fuji-LAS-1000 imaging system.
2.6. Monitoring tumor growth in vivo
Cells (Control, MCF-7-PP5s or MCF-7-PP5j) were grown to 80–90%
confluence, detached from the dish with 2 mM EDTA, and washed with cold
PBS. Aliquots were then counted using a hemacytometer and each cell line was
resuspended in ice-cold HBSS to a final concentration of 1.2×107 cells/ml. The
cell suspensions (100 μl) were injected into exposed axillary mammary fat pads
of anaesthetized (Ketamine 80 mg/kg, Xylazine 14 mg/kg) 4–5 weeks old,
female athymic mice. Tumor size was measured weekly by taking orthogonal
measurements and was expressed as mean tumor diameter. Mean tumor dia-
meter was calculated by taking the square root of the product of orthogonal
measurements as described previously [25]. Animals were maintained under
the guidelines of the National Institute of Health and the University of South
Alabama. All protocols were approved by the Institutional Animal Care and Use
Committee (IACUC). Food and water were provided ad libitum.
2.7. UVC treatment
Cells were plated at 3×105 cells per 60 mm dish and grown overnight. The
dishes were washed with PBS. The PBS was removed and the plates were
exposed to the indicated amount of UVC by placing the plates in a Class II A/B3
Biological Safety Cabinet (Forma Scientific) with a 60w UV light. UVC ex-
posure was measured using a Multi-Sense 100 UV monitor equipped with an
MP-125UV-C sensor (UVP, Cambridge, UK).
2.8. Confocal image analysis
Samples were fixed in methanol and examined using a Leica TCS SP2
system equipped with Argon and Krypton lasers. Confocal images were vi-
sualized with a 63× oil objective and twenty optical sections were analyzed per
cell.
2.9. Tissue microarrays (TMAs)
Tissue microarray slides were obtained from the Cooperative Breast Cancer
Tissue Resource (CBCTR; National Cancer Institute). Each TMA contains 252
normal breast and breast cancer cores and 36 additional controls. The cores
appearing on each TMA block include: 1) node-negative breast cancer (64
cores), 2) node-positive breast cancer (64 cores), 3) metastatic breast cancer (64
cores), 4) ductal carcinoma in situ [DCIS; 20 cores (10 from individuals without
an invasive disease component and 10 from individuals with invasive disease
represented elsewhere on the TMA)], 5) normal Breast tissue (40 cores; 20 from
individuals without breast cancer and 20 cores of normal adjacent tissue from
individuals with breast cancer represented elsewhere on the TMA). The 36
control cores appearing on each TMA block include normal non-breast tissue
(16 cores; 4 from each of the following tissue types: kidney, endometrium,
prostate and appendix) and human cell lines (20 cores; 5 cores from each of the
following cell lines: HT-29, PC-3, MCF-7 and T-47D).
2.10. Immunohistochemistry
To visualize PP5 in fixed tissue, after deparaffinization and rehydration
endogenous peroxidase activity was blocked by placing the samples in methanol
containing 0.3% hydrogen peroxide for 30 min For antigen recovery, the tissue
sections were placed in a coplin jar containing citrate buffer (pH 6.0), and the jar
was placed in a steamer and heated (95 °C) for 20 min Prior to incubation with
the primary antibody the samples were subjected to a 20-min cool off period.
Then the tissue sections were loaded onto a Dako autostainer, where it was
incubated with PP5 monoclonal antibody (BD Biosciences), washed and
visualized. Visualization was achieved using the LSAB+(LASB, HRP; labeled
streptavidin-biotin, horseradish peroxidase) visualization system from Dako-
Cytomation (Carpinterias, CA). The cells were then counterstained withMayer's
Hematoxylin.2.11. Fluorescence activated cell sorting (FACS) and analysis of cell
growth
FACS-analysis was achieved using Vantage SE flow cytometer (Becton
Dickinson Immunocytometry Systems, BDIS, San Jose, CA) employing pulse
processing (FL2-width and FL2-area) to gate out cell doublets and ModFitLT
cell cycle analysis software (Verity Software House, Topsham, ME). Propidium
Iodine (PI) fluorescence was excited at 488 nm with an argon laser (Spectra
Physics, Sunnyvale, CA) and fluorescence emission was collected with a 582/42
BP filter in front to the FL2 detector. Detection of GFP (green fluorescence;
FL1) for cell sorting was measured using a 530/30 nm band pass filter.
Multivariate data acquisition and analysis was performed with BDIS Cell Quest
software.
2.12. Cell proliferation
Cell numbers were routinely determined by counting the number of cells
using a Coulter Counter™ (Z1). For these experiments the indicated types of
cells were plated at an equal density in 60 mm tissue culture plates, with the
number of plates used sufficient for duplicate or triplicate measurements at each
time point, including time zero plates (to detect inconsistencies in initial plating
density). At the times indicated, the cells were detached from the dish by brief
treatment with trypsin, and the number of cells were counted using a Z1 coulter
Counter. The survival of cells was also assessed using a metabolic assay, Via-
Light Plus cell proliferation kit (Cambrex), according to the instructions provided
by the manufacturer.
2.13. Statistical methods
To evaluate whether the frequency of specimens with the elevated levels
of PP5 increased during breast carcinogenesis, the Fisher's exact test was em-
ployed, grouping the results as normal, invasive cancer, invasive node-negative,
invasive node-positive, and invasive with distant metastases. P values of less
than 0.05 were regarded as statistically significant.
3. Results
3.1. Elevated PP5 protein levels in human breast cancer
Western analysis comparing PP5 protein levels in samples of
freshly isolated human tumors (diagnosed as invasive ductal
carcinomas with metastatic lesions at the time of diagnosis) and
samples of ductal epithelial tissue (obtained from patients under-
going breast reduction surgery and demonstrating no indication
of disease) revealed elevated levels of PP5 in the tumors. Si-
milarly, analysis of same-patient samples (comparing infiltrating
ductal carcinomas from breast and normal adjacent breast epi-
thelium) revealed an increase in PP5 protein levels in the tumor
tissue (supplied as Supplementary data, Fig. 1S). These initial
observations suggest that PP5 levels may be elevated in human
breast cancer. To determine if the expression of PP5 indeed
correlates with the development of human breast cancer, tissue
micro-arrays (TMAs) were obtained from the Cooperative Breast
Cancer Tissue Resource (CBCTR;National Cancer Institute). For
these studies Breast Tissue Progression TMAs were employed,
which were designed by NCI statisticians to provide high sta-
tistical power for studies of stage specific markers of breast
cancer. Each array consists of 288 cores (0.6 mm) taken from
paraffin-embedded specimens that represent 212 breast cancer
and 40 normal breast specimens (20 cores from individuals
without breast cancer and 20 cores of normal adjacent tissue from
individuals with breast cancer), along with 36 controls (normal
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are primary breast cancers with a principal histology of ductal
carcinoma, and the TMAs contain samples representing three
stages of invasive breast cancer: node-negative, node-positive
andmetastatic disease. To address issues related to possible tissue
heterogeneity, four cores were taken from each specimen block,
with one core per specimen appearing in each of the four replicateFig. 1. Analysis of human tissue to detect PP5 protein. Representative immunostain
employing the anti-PP5 monoclonal antibody. The data shown are representative N28
cells were counter stained with Mayer's Hematoxylin, and the TMAs are described
carcinoma in situ.array blocks. For each case tumor size, TMN stage, number of
positive nodes, grade, age at diagnosis and race was known. In
addition for many samples, ER, PR, HER-2 status was also
known. Here, each array was stained using the monoclonal
antibody to PP5. The samples were then independently scored
for intensity of PP5 staining by two pathologists (0=background/
no staining, 1=staining, 2=strong staining, and 3=intense PP5ing of TMAs illustrating primary human breast cancer and normal breast tissue
0 samples appearing on each TMAs and the scoring (0, 1, 2, 3) is indicated. The
in more detail under Methods. IDC; invasive ductal carcinoma. DCIS; ductal
263T. Golden et al. / Biochimica et Biophysica Acta 1782 (2008) 259–270staining). Representative immuno-stained samples are shown in
Fig. 1. The 0.6 mm cores afforded some histological information,
which allowed confirmation of the diagnosis reported on the key.
In the few instances in which normal adjacent tissue was present
in an area that was keyed as tumor, the additional normal tissue
was scored and the data were included with the normal tissue
controls for statistical analysis.
For the normal breast and normal adjacent tissues samples
tested, 77% were scored as 0, and 23% were scored as 1. No
samples of normal breast tissue were scored as 2 or 3. In com-
parison, 58.3% of the invasive tumor samples stained positive
for PP5 (62% of the positive staining tumors were scored as 1,
26% as 2 and 12% as 3). Fisher's exact analysis of the data
indicated a statistically significant difference in PP5 staining
in normal vs ductal carcinoma in situ (DCIS) and normal vs
invasive ductal carcinoma (IDC), with the strongest correlation
between PP5 staining and IDC with distal metastases at the time
of diagnosis (Table 1). Analyses failed to reveal a statistically
significant correlation between PP5 expression and ER, HER-2,
age, tumor grade or tumor size. Sub-analysis of samples scored
as over-expressing PP5 also failed to reveal a correlation be-
tween PP5 expression and HER-2, ER, or PR expression. To-
gether, these studies revealed a positive correlation between high
levels of PP5 and human breast cancer.
3.2. Growth effects of constitutive PP5 over-expression in
MCF-7 cells
Although a number of studies have investigated cellular
events altered by the suppression of PP5 expression [10–12,
14,16,18,20,21] little is known about the consequences of over-
expression. Therefore, we developed PP5-expression vectors
for use in transient transfection studies and for the generation
of stable cell lines that over-express PP5 in trans. In one system,
to help monitor PP5-expression an EGFP-tag was added to the
C-terminus of PP5, creating a PP5-EGFP fusion-protein. The
EGFP-tag was added to the C-terminal because structural and
modeling [26–28] studies indicate that the N-terminal TPR-
domains mediate the interaction of PP5 with protein complexes
containing substrates [7,28–30]. Such studies also indicate that
the C-terminal J-helix, which is displaced from its contactsTable 1
Fisher's exact test for PP5-staining; two sided
P Value (S=significant)
Normal vs. IDC 0.012 (S)
Normal vs. DCIS 0.0028 (S)
Normal vs. IDC with distal metastasis
at the time of diagnosis
0.0001 (S)
Sub-analysis
IDC vs. HER-2 0.394
IDC vs. ER 0.7
IDC vs. PR 0.447
IDC, invasive ductal carcinoma; DCIS ductal carcinoma in situ; ER, estrogen
receptor; PR, progesterone receptor; HER-2, HER-2/neu proto-oncogene; S,
statistically significant. TMAs were obtained from the CBCTR and PP5 was
visualized using a monoclonal antibody that recognizes PP5 (see Materials and
methods for additional detail).within an N-terminal inhibitory by “TPR-mediated docking”
[28], is connected to the catalytic domain by a flexible loop
[26]. Thus, when associated with proteins, such as HSP-90, it
was predicted that the addition of the EGFP-tag to this region
would minimize the potential for artifacts produced by the
addition of the EGFP-tag. A catalytically inactive form of PP5
can be created by mutating His304, or other key amino acids that
form the active sight [26]. However, the over-expression of
inactive PP5, or even the TPR-domain of PP5, produces a
dominant negative effect [7,30]. Therefore, as an additional
control we also employed a second expression system (PP5-tet-
off). In this system the constitutive expression of exogenous
PP5 is induced by the removal of tetracycline from the culture
medium [21]. To characterize these expression systems, PP5
protein levels were measured following transfection, using
western analysis to monitor levels of PP5 protein and FACS-
analysis (fluorescence activated cell sorting) to measure PP5-
EGFP and EGFP. As seen in Fig. 2, FACS-analysis of MCF-7
cells 24 h after transfection with expression plasmids encoding
either a PP5-EGFP fusion-protein or EGFP alone revealed si-
milar fluorescence profiles (Fig. 2; compare A and B). This
indicates that both proteins are efficiently expressed in MCF-7
cells.
To test the effect of PP5 expression on the rate of cell growth,
MCF-7 cells transfected with expression vectors encoding PP5-
EGFP, or EGFP as a control, were sorted into seven groups
based on fluorescence using a flow cytometer. The groups were
arbitrarily designated R1 to R7 (shown in Fig. 2), with R1
representing the highest level of florescence that could be
achieved and R7 representing background fluorescence (i.e.
cells that were not transfected or cells that failed to express the
protein encoded in the plasmids). Cells from each group were
then seeded at equal density in 96 well plates and cell prolife-
ration was quantitated at the times indicated. As seen in Fig. 2C,
when compared to the controls, even a modest increase in PP5
expression is associated with an increased rate of proliferation.
However, at very high levels, (i.e. R1 and R2) the cells failed to
proliferate and were dead ∼24–72 h after transfection.
Fluorescence microscopic examination of the transfected
cells revealed fluorescence in both the cytoplasm and nucleus of
cells expressing the EGFP-tag alone. In contrast, in cells over-
expressing PP5-EGFP fluorescence was observed predomi-
nately in the cytoplasm, which is consistent with the cellular
distribution of endogenous PP5 determined by immunostaining
of MCF-7 cells [30]. Thus, with modest over-expression the
PP5-EGFP fusion-protein was distributed within the cells with a
pattern similar to that of native PP5. When PP5-EGFP was
expressed at very high levels (e.g. R1-R2), intense fluorescence
was observed in both the cytosol and nucleus. Still, as noted
above these cells died in b72 h, and at very high levels the over-
expressed proteins may affect processes other then those nor-
mally acted upon by PP5.
Next more than 10 stable MCF-7 cell lines were generated
and analyzed by FACS and Western analysis. Using the tet-off
expression system several cell lines in which PP5-expression
was induced ∼1.5–2 fold upon tetracycline removal were ob-
tained, and one (designated as MCF-7-PP5h1) was chosen for
Fig. 2. Expression levels of PP5, PP5-EGFP and EGFP in MCF-7 cells. A) Fluorescence activated cell sorting (FACS) analysis of MCF-7 cells 24 h after transfection
with pEGFP. B) FACS-analysis ofMCF-7 cells 24 h after transfection with pPP5-EGFP.MCF-7 cells in log phase growth were transfected with the expression plasmids
encoding EGFP or a PP5-EGFP fusion-protein. After 24 h the cell cultures were processed for FACS-analysis as described in Methods. For A and B the data shown are
histograms of 10,000 cells illustrating the intensity of GFP-fluorescence (y-axis) plotted against size/forward scatter (FSC-height; x-axis). Gates were set to exclude
necrotic cells and cell debris. The GFP-florescence intensity was divided arbitrarily into seven equal regions (R1-R7) with R1 representing the cells with the greatest
intensity. For each experiment duplicate samples were processed to obtain cell cycle profiles within each gated region using propidium iodide staining. The experiments
shown are representative of 3 separate experiments that produced similar results. C) Comparison of the relative growth rate and the amount of PP5-EGFP expression.
MCF-7 cells were transfected with expression plasmids encoding EGFP or PP5-EGFP. After 24 h, cells expressing PP5-EGFP or EGFP alone were sorted based on
fluorescence intensity into seven fractions (R1-R-7; as indicated above) and plated (100 cells/well) into 96-well plates. After 6 days cell numbers were determined using
a metabolic proliferation (ViaLight Plus) assay. The data are plotted as growth rate vs fluorescence, with the proliferation rate of PP5-EGFP expressing cells plotted as
the % of controls (i.e. the rate of proliferation for cells expressing EGFP alone). The proliferation rate assays were measured in triplicate and plotted as the mean±SD.
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stronger CMV promoter employed in the EGFP-fusion expres-
sion system, and two lines (MCF-7-PP5s and MCF-7-PP5j) that
overexpressed PP5-EGFP at higher levels (Fig. 3A) were also
chosen for further studies. Fluorescent images showing the
cytoplasmic expression of PP5-EGFP and the nuclear and cyto-
plasmic expression of EGFP in representative MCF-7 cell lines
are shown in Fig. 3B. Again cells over-expressing either PP5 or
PP5-EGFP proliferate faster then controls (Fig. 3C).
3.3. Constitutive over-expression of PP5 aids tumor growth in
mice
The ability of forced PP5 over-expression to facilitate pro-
liferation in MCF-7 cell cultures suggests that aberrant PP5expression may contribute to the development of cancer. To
investigate the possibility that PP5 may play a role in tumor
growth, we next studied the affect of constitutive elevated PP5
expression on the formation and growth rate of MCF-7 tumors
using a mouse xenograft model. For these studies MCF-7 cell
lines that over express different amounts of PP5 were injected
into the axillary mammary fat pads of 4–5 week old, female
athymic mice. Three groups of mice were used in two separate
experiments, with a total of 12 mice per group. Group one
animals were used to test the effect of moderate PP5 over
expression (similar to levels designated as 2+ in the TMAs).
Animals in this group were injected with the cell line MCF-7-
PP5s, which over expresses PP5-EGFP at a level that is ∼3–4
times the level of PP5 observed in the parental MCF-7 cells
(Fig. 3). Group two animals were injected with the cell line
Fig. 3. Expression of PP5 and PP5-EGFP in MCF-7 cells. A) Western analysis illustrating the amount of PP5 and PP5-EGFP protein levels in MCF-7 cells and stable
MCF-7 cell lines constitutively over-expressing PP5 (MCF-7-PP5h1) or PP5-EGFP (MCF-7-PP5s, MCF-7-PP5j). Open bars indicate the amount of native PP5
(migrates on SDS-PAGE at the same rate as a ∼56 KD marker). Filled bars indicate PP5-EGFP, which migrates more slowly (see insert in Fig. 4). The level of
expression is based on the quantitated levels of protein detected by Western analysis. PP5 was detected using a polyclonal antibody to PP5 [10]. The data shown
represent the average protein levels of the indicated protein obtained from measuring protein each day over the course of 3 days during which the cells were in
exponential growth. For MCF-7-PP5h1 cells, the induction of PP5 was induced by the removal of tetracycline from the media two days prior to the start of the
experiment. The data are plotted as a percentage of controls (MCF-7 cells in log phase growth) and are normalized to actin measured on the same membrane to account
for any inconsistency in loading or protein transfer. The data shown (mean±SEM) are representative of at least 3 similar experiments. B) Fluorescent images taken of
representative cells from cell lines expressing EGFP alone (MCF-7-EGFP) or PP5-EGFP (MCF-7-PP5s, MCF-7-PP5j). C) Growth curves showing the proliferation
rate of stable MCF-7 cells over-expressing PP5 (MCF-7-PP5h1; filled squares) PP5-EGFP (MCF-7-PP5s; filled triangles) EGFP (MCF-7-EGFP; open triangles) and
the parental MCF-7 cells with “normal” levels of PP5 (MCF-7: open squares). For each cell line replicate plates of cells were plated at equal density at day 0. At the
times indicated, the number of cells in replicate plates was determined using a Coulter Counter. The data shown are plotted as the mean±SD of 3 or more independent
experiments each conducted in duplicate. For MCF-7-PP5h1 cells, the expression of PP5 was induced by the removal of tetracycline from the media 2 days prior to the
beginning of the experiment to allow for full induction of PP5 expression.
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still maintained cytoplasmic fluorescence). The third group
served as a control. The animals in the control group were
injected withMCF-7 cells expressing EGFP alone (EGFP-CTL).
A comparison of tumor development in mice injected with
MCF-7 cells expressing varying amounts of PP5 is shown in
Fig. 4. For group 1, tumors were produced in 9 of 12 mice. In
the mice that produced tumors, the tumors were apparent after
∼2 weeks, and by day 35 the mean tumor diameter was 1.75±
0.37 mm, which is significantly different from controls (Pb
0.01). In the group two animals tumors were produced in 10 of
12 animals, were apparent by ∼2 weeks and had a mean tumor
diameter of 3.75±0.68 (Pb0.002 vs. controls) after 35 days.
For control mice, 5 of 12 had detectable tumors by day 35.
However, the tumors were not detectable until day∼24, and the
mean diameters (0.52±0.26 mm) were consistently smaller than
the tumors in mice injected with cells over-expressing PP5.
3.4. Constitutive over-expression of PP5 protects MCF-7 cells
from oxidative stress, UVC-irradiation, adriamycin, and
vinblastine induced death
Previous studies have shown that the suppression of PP5
expression can enhance signaling-cascades that induce apopto-
sis in response to DNA damage, oxidative stress, and UV-
irradiation [4,10,13,14,16,18]. To determine if PP5 over expres-
sion has the opposite effect (i.e. protects cells from genomic
stress-induced death) we treated MCF-7 cells over-expressing
PP5 with several agents that activate signaling networks known
to be influenced by PP5. As seen in Fig. 5, in MCF-7-PP5h1
cells with normal levels of PP5 t-butyl hydroperoxide produces
a dose-dependent decrease in cell viability, with 50 μM andFig. 4. Constitutive over expression of PP5 enhances tumor growth in vivo.
MCF-7 cells which overexpressed PP5-EGFP (MCF-7-PP5s and MCF-7-PP5j)
or EGFP alone (control) were injected into the axillary mammary fat pads of
4–5 week old, female athymic mice as described in methods. Tumor size was
then assessed at the times indicated, starting ∼7 days after injection. The data
shown represents two experiments, with a total of 12 mice injected with each cell
line. The number of animals that produced tumors is shown to the right of each
line, and the data is plotted as the mean diameter (±SEM) of the tumors observed.
Insert: Western analysis of PP5 and PP5-EGFP fusion-protein in the three cell
lines detected with an antibody that recognizes PP5 (C, control MCF-7; PP5s,
MCF-7-PP5, PP5j, MCF-7-PP5j).100 μM t-butyl hydroperoxide killing ∼39 and ∼90% of the
cells, respectively, in 24 h In contrast, when PP5 expression is
induced by the removal of tetracycline from the media ∼48 h
prior to treatment, even a modest increase in PP5 protein levels
increased 24 h survival, with 50 μM and 100 μM t-butyl hy-
droperoxide killing 0 and 51% of the treated cells, respectively.
Both in the presence and absence of tetracycline, pretreatment
(16 h) with N-acetyl-L cysteine (30 mM) suppressed H2O2
induced death. In addition, the withdrawal of serum from the
media, which induces ROS productions at lower levels [31,32],
did not affect cell survival (Table 2). Both DAPI staining, which
revealed fragmented nuclei (not shown), and PARP cleavage
assays (Fig. 5A insert) are consistent with t-butyl hydroperoxide
induced death occurring via apoptosis.
The effect of PP5 over-expression on UVC-stress was mea-
sured by exposing MCF-7, MCF-7-PP5h1, MCF-7-PP5s and
MCF-7-EGFP cells to increasing amounts of UVC and counting
viable cells over a 72 h period.WithMCF-7 cells UVC-irradiation
induces an apoptotic response [33], and 24 h after exposure to a
lethal dose of UVC (30 mJ) the survival of both control cell lines
(MCF-7 and MCF-7-EGFP) was dramatically reduced (Table 2).
By 72 h MCF-7 cells expressing normal levels of PP5 that were
exposed to 30mJUVCwere essentially all dead. Exposure of PP5
over-expressing cells to UVC also resulted in a decrease in sur-
vival. However, both cell lines over-expressing PP5 had a sta-
tistically significant difference in survival by 24 h (Table 2). After
48 h the survival difference between cells with normal levels
of PP5 and those over-expressing PP5 was visually obvious
(Fig. 5C). In the controls, few to no cells remain attached to the
plate, and the floating cells are rounded and blebbing. In contrast,
cultures of PP5 over-expressing MCF-7 cells contained many
viable cells that remain attached to the dish.
The effects of PP5 expression on cell survival following
treatment with adriamycin (doxorubicin), was investigated next.
The molecular actions of adriamycin toxicity are complex. Ad-
riamycin 1) intercalates with DNA, directly affecting transcrip-
tion, 2) forms a tripartite complex with topoisomerase II and
DNA, resulting in double-strand breaks, and 3) by virtue of its
quinone group also generate free radicals [34]. A key part of its
antitumor activity appears to result from its ability to trigger a
strong DNA-damage response that actives p53 and results in
apoptosis (for rev. see [34]). However adriamycin-induced
apoptosis is suppressed by the induction of the G1-cyclin kinase
inhibitor protein, p21Waf1/cip1, which induces G1-growth arrest
[35,36]. Because the suppression of PP5 was associated both
the activation of p53 and the induction of p21Waf1/cip1 expres-
sion, without spontaneously inducing apoptosis [11], prelimin-
ary time-course and dose-response experiments were conducted
to identify the LD50 and LD100 (concentration needed to kill 50%
and 100% of the treated cells, respectively) in MCF-7 cells.
Similar studies were also conducted using vinblastine, taxol, and
rapamycin. Then the effects of PP5 over-expression on survival
were tested by treating MCF-7, MCF-7-EGFP, MCF-7-PP5h1
and MCF-7-PP5s with each compound at a level that kills ∼50,
70 or 100% of the control cells at the times indicated. Differ-
ences in cell survival were determined by counting the number
of cells in each dish at the times indicated using a Coulter
Fig. 5. Constitutive over-expression of PP5 protects MCF-7 cells from stress-induced death. A) MCF-7-PP5h1 were plated in 96 well plates and grown in the presence
(normal levels of PP5; open bars) or absence of tetracycline (to induce PP5 expression; filled bars). After 48 h, the indicated concentration of t-butyl-hydroperoxide
was added and the cells were incubated for 24 h at 37 °C. Viable cells were then measured using a metabolic assay as above. The data shown represent the mean±SEM
of three independent experiments each conducted in triplicate. Insert: immunoblot showing cleavage of poly ADP-ribose polymerase (PARP) in cells with normal
levels of PP5 at the indicated times following treatment with 200 μM hydrogen peroxide. B) Western blot showing the correlation between an increase in PP5 levels in
MCF-7-PP5h1 cells and the suppression of t-butyl hydroperoxide (25 μM) induced phosphorylation of MKK4 (Thr262) and c-Jun (Ser63). Lane 1, normal expression of
PP5 in MCF-7-PP5h1. Lane 2, increased expression of PP5 induced by the removal of tetracycline from the media [21]. Western blots were conducted as described in
Methods, and the data shown are representative of 3 independent experiments. C) Phase contrast pictures of MCF-7 control cells (left panels) and MCF-7 cells
constitutively over-expressing PP5-EGFP fusion-protein (MCF-7-PP5s) 48 h after UVC (30 mJ) exposure. Controls were not exposed to UVC. The pictures shown are
representative of N4 separate experiments and the quantitative survival data are shown in Table 2.
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over-expressing PP5 were less sensitive to adriamycin or vin-
blastine, while no difference in survival was observed when cells
were treated with taxol, rapamycin, or the combination of serum
withdrawal and rapamycin (Table 2). Remarkably, the over-
expression of PP5 provided partial protection from 48 h treat-
ment with 1.0 μg/ml (1.7 μM) adriamycin, a dose that kills
N50% of the controls in 24 h, N95% of controls in 48 h (Fig. 6A)
and is∼5 times the amount needed to induce nearly 100% death
in MCF-7 cells that are exposed to this drug for 72 h. At a lower
concentration (0.2 μg/ml) both cells with normal and elevatedlevels of PP5 are rapidly growth arrested by adriamycin (Fig. 6 B).
However, when the drug was removed after 72 h, by day 6 the
control cells showed marked membranes blebbing. By day 10
the controls were essentially all dead. In contrast, after the initial
growth arrest, the cells with elevated PP5 did not die. Rather, the
MCF-7-PP5h1 cells remained viable, and by days 6–7 the cul-
tures contained proliferating cells. A statistically significant
difference was achieved by day 7 at which time the MCF-7-
PP5h1 cell over-expressing PP5 entered into log phase growth
(Fig. 6B). By day 10 the MCF-7-PP5h1 cell cultures were
confluent, while only a few control cells remained attached to the
Table 2
Effect of PP5 over-expression on MCF-7 cell survival following treatment with agents that induce apoptosis in MCF-7 cells
Treatment: UVC (30 mJ) Adriamycin (1.7 μM) Vinblastine (20 nM) Taxol (50 nM) Rapamycin (200 nM) Serum starvation Rapamycin (200 nM)
plus serum starvation
Duration of treatment:
24 h 48 h 72 h
Percentage of cell survival; treated/control (mean±SD):
Cell line:
MCF-7-EGFP 28.2±1.8 42.8±5.9 33.4±0.8 30±0 64.5±6.7 45.9±2.8 40.0±5.4
MCF-7-PP5s 47.3±4.8 60.6±9.9 38.8±0.7 36.5±6.4 59.5±12.8 42.8±10.2 36.4±8.3
P value Pb0.003 Pb0.05 Pb0.02 Pb0.5 Pb0.7 Pb0.7 Pb0.7
MCF-7 33.3±3.2 40.5±3.2 31.6±0.9 39.4±3.7 ND ND ND
MCF-7-PP5h1 48.8±3.1 49.0±2.8 39.7±0.4 36.8±2.0 ND ND ND
P value Pb0.004 Pb0.002 Pb0.007 Pb0.3 ND ND ND
Replicate plates of the indicated cell lines were produced by plating cells at equal density. After 24 h, the cells were treated with the agents shown, and at the times
indicated the number of cells in duplicate plates was determined by cell counting using a Coulter Counter. The data shown are the mean of 4 experiments±SD.
P values were determined by using the Students t-test (unpaired, two-tailed), and each P value represents a comparison of treated PP5 over-expressing cells to treated
control cells (MCF-7PP5s vs. MCF-7-EFGP; MCF-7 vs. MCF-7-PP5h1). P values of less than 0.05 were regarded as significant and are indicated by bold font.
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that the over-expression of PP5 had no apparent effect on
adriamycin-induced p21Waf1/cip1 expression, which was mark-
edly induced in all of the treated cells (data not shown).
4. Discussion
Previous studies have shown that the suppression of PP5
expression with siRNA or antisense oligonuclotides results in
the augmentation or prolongation of signaling-cascades that are
activated by agents that produce genomic stress [10–12,14,16,
18,20,21]. Still, the physiological/pathological roles played by
PP5 are not well understood. In the present study elevated levels
of PP5 protein were detected in specimens of human breast
cancer [ductal carcinoma in situ (DCIS) and invasive ductal
carcinoma (IDC) of the breast], with the strongest correlation
observed between high levels of PP5 and IDC in patients with
metastatic disease at the time of diagnosis (Pb0.0001). A
correlation between PP5 over-expression and accelerated tumor
growth was also observed in a xenograft mouse model for tumor
development. These findings indicate that PP5 over-expression
correlates with the development of human breast cancer, and
suggest that PP5 may aid tumor growth. To our knowledge this
is the first report of a functional positive correlation between
elevated levels of PP5 and the development of human breast
cancer. In rats, however, PP5 mRNA levels were reported as
markedly elevated in highly malignant ascites hepatomas [37],
and in yeast the homologue of PP5 (PPT1) is expressed at
elevated levels in proliferating cells [38]. Recently, a proteomic
analysis of mantle-cell lymphoma by protein microarray also
revealed elevated PP5 expression [39], which may implicate
PP5 over-expression in other cancers.
At the molecular level, the relationship between PP5 ex-
pression and tumor growth is not yet clear. The human PP5-
promoter contains a functional estrogen response element, and
in some estrogen responsive cells 17-β-estradiol induces PP5
expression [21]. The over-expression of PP5 has been reported
to suppress ER-mediated transcription [40]. Still the suppres-sion of PP5 expression with antisense oligonucleotides does not
affect estradiol-induced expression of classic ER-responsive
genes (e.g. c-myc or cyclin D1) [21]. Together, these observa-
tions suggest that PP5 may act as a feedback inhibitor of ER-
signaling. Here we observed that the constitutive over-expres-
sion of PP5 results in an increase in the growth rate of MCF-7
cells both in cell culture and in mouse xenograft tumors when
estrogen levels are normal. However, the analysis of the human
TMA data failed to reveal a correlation between high levels of
PP5 and estrogen receptor expression (Table 1). In addition in
our previous studies we have shown that in a low estrogen
environment (subcutaneous injections in male NCR (Taconic)
nude mice) the over-expression of PP5 alone is not sufficient to
produce xenograft tumors [22]. Therefore, although PP5 may
play a role in a feedback mechanism that regulates the actions of
ERs, the ability of PP5 to aid tumor growth may be down stream
or independent from its actions on ERs.
Studies with siRNA and antisense oligonucleotides indicate
that a decrease in PP5 expression can also result in G1-growth
arrest [10,11], DNA-damage checkpoint control failure [18],
prolonged activation of ASK1-signaling [13,14], altered DNA-
PKcs signaling [16], and a GR/p53-dependent increase in
p21Waf1/cip1 expression [10,11]. These observations led us to
test the hypothesis that the over-expression of PP5 may provide
cells with protection from stress-induced growth arrest/death. In
the present studies, dose-response cell survival experiments
were conducted using t-butyl hydroperoxide, UVC-irradiation,
adriamycin, and other antitumor drugs that induce growth arrest
or apoptosis in MCF-7 cells via signaling networks that PP5 is
known to influence [41–44]. The data obtained indicates that
the over-expression of PP5 provides protection from UVC-
irradiation, adriamycin and vinblastine. In contrast, no apparent
protection was observed following treatment with taxol, rapa-
mycin, serum starvation or concomitant serum starvation and
rapamycin treatment (Table 2). All of the reagents that PP5
over-expression provides protection from are known to induce
oxidative stress, DNA-damage, or both. They also lead to the
activation of ASK1, DNA-PKcs, p53 and/or apoptosis. Since
Fig. 6. Over-expression of PP5 suppresses adriamycin-induced death in MCF-7
cells. A) Phase contrast pictures of MCF-7 cells and cells over-expressing PP5-
EGFP (MCF-7-PP5s) 48 h after treatment with 1.0 μg/ml adriamycin (1.7 μM).
The pictures shown are representative of 4 separate experiments and the quan-
titative 24-h survival data are shown in Table 2. B) Growth curves of MCF-7
cells. MCF-7-PP5h1 cells cultured in the presence (+tet; normal PP5) or ab-
sences of tetracycline (− tet; increased PP5) for 48 h Replicate plates were
seeded at equal density, and after 24 h the plates were treated with 0.2 μg/mL
adriamycin (filled symbols) or solvent alone (open symbols). After 3 days the
cells treated with adriamycin were washed and given fresh media (indicated by
an arrow). The number of cells in replicate plates was determined at the times
indicated by cell counting with a Coulter Counter. The data shown are plotted as
the mean (±SD) of replicate dishes from a single experiment and are repre-
sentative of 4 separate experiments that produced similar results. The over-
expression of PP5 in MCF-7-PP5h1 cells was induced by the removal of
tetracycline (− tet) from the media as described above (Fig. 5).
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13,14,45,46], p53 [10,12], and DNA-PKcs [16], the observed
increase in cell survival associated with PP5 over-expression is
consistent with the concept that PP5 acts to suppress established
signaling-cascades (i.e. ASK1-, p53-and/or DNA-PK-induced)
that normally trigger an apoptotic response. In support of pre-
vious studies examining the relationship between PP5 and
ASK1-signaling networks [13,14], a modest increase in PP5
expression was associated with the suppression of MKK4 and
c-Jun phosphorylation (Fig. 5 B), which in response to hypoxia
or H2O2 are maintained in a hyperphosphorylated when PP5
proteins levels are suppressed [14]. However, PP5 has also been
implicated in the regulation of Raf-1 signaling [20], and it is
also possible that PP5 affects yet another currently unrecog-
nized growth-control mechanisms. Therefore, at this time the
increase in MCF-7 tumor size observed in the xenograft model
of PP5 over-expression cannot be assigned to the suppression of
a single pathway.Previous studies have also implicated PP5 in the antiproli-
ferative effects of rapamycin, with rapamycin producing a de-
crease in PP5 activity that subsequently leads to an increase in
ASK1-mediated apoptosis [45]. At first glance, because PP5
over-expression in MCF-7 cells did not provide resistance to
treatment with rapamycin, or the combination of rapamycin and
serum withdrawal, our data appears inconsistent with the initial
observation. However, the role for PP5 in rapamycin mediated
activation of ASK1 and apoptosis was only observed in p53−/−
cells, and MCF-7 cells are p53-wildtype. Thus, the different
observations are not in conflict. Rather, both studies support the
hypothesis proposed by Huang et al. [45,46] suggesting p53
acts to suppress rapamycin-induced activation of ASK1 [45,46].
Finally it should be noted that although the over-expression
of PP5 allowed MCF-7 cells to withstand higher doses of UVC,
t-butyl hydroperoxide, and adriamycin, we did not observe an
increase in MCF-7 cell sensitivity to these agents when the
expression of PP5 was suppressed. In addition the suppression
of PP5 expression with siRNA in the absence of DNA-damage/
stress does not result in cell death [10,11,14]. Thus, although the
over-expression of PP5 may aid cell survival in the presence of
stress, the suppression of PP5 without the concomitant activa-
tion of a stress-induced response does not trigger apoptosis.
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